AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
AN2 Therapeutics Inc <ANTX.OQ> expected to post a loss of 27 cents a share - Earnings Preview
AN2 Therapeutics Inc ANTX.OQ ANTX.O is expected to show no change in quarterly revenue when it reports results on August 10 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for AN2 Therapeutics Inc is for a loss of 27 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AN2 Therapeutics Inc is $9.00, about 48% above its last closing price of $6.08
This summary was machine generated August 7 at 14:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview